ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
ASLN was delisted on the 18th of July, 2024.
8 hedge funds and large institutions have $10.7M invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2019 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
2% less capital invested
Capital invested by funds: $11M → $10.7M (-$267K)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$388K |
| 2 |
Jane Street
New York
|
+$44.6K |
| 3 |
FIA
FNY Investment Advisers
New York
|
+$1.94K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HSBC Holdings
London,
United Kingdom
|
-$1.26M |
| 2 |
PSCM
Prince Street Capital Management
New York
|
-$920K |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$29.5K |
| 4 |
Millennium Management
New York
|
-$11.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.49K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Temasek Holdings
Singapore
| $6.1M | – | – | – |
|
|
2
Baillie Gifford & Co
Edinburgh,
United Kingdom
| $1.84M | -$29.5K | -198 | -2% |
|
|
PIM
3
Platinum Investment Management
Sydney Australia 2000,
Australia
| $1.67M | +$388K | +2,598 | +37% |
|
|
4
HSBC Holdings
London,
United Kingdom
| $855K | -$1.26M | -8,436 | -63% |
|
|
FIA
5
FNY Investment Advisers
New York
| $111K | +$1.94K | +13 | +2% |
|
|
6
Millennium Management
New York
| $62K | -$11.8K | -79 | -17% |
|
|
7
Jane Street
New York
| $52K | +$44.6K | +299 | New |
|
|
8
UBS Group
Zurich,
Switzerland
| $14K | -$1.49K | -10 | -11% |
|
|
PSCM
9
Prince Street Capital Management
New York
| – | -$920K | -6,390 | Closed |
|
ASLN Hedge Fund Activity: Q1 2019 in Review
8 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q1 2019, worth a combined $10.7M — down 2.4% from $11M a quarter earlier.
Fund positioning in ASLN was balanced in Q1 2019: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 4 trimmed.
The largest buyer was Platinum Investment Management, adding an estimated $388K. The largest seller was HSBC Holdings, cutting an estimated $1.26M.
- 8 institutional investors held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $10.7M of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q1 2019, down 2.4% quarter-over-quarter.
- 1 fund opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q1 2019 and 1 closed out, a net change of 0 holders.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares buyer in Q1 2019 was Platinum Investment Management, an estimated $388K added.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q1 2019 was HSBC Holdings, an estimated $1.26M sold.
Based on aggregated 13F filings for Q1 2019.